Complete Proscia $ 1M seed round funding to advance cancer diagnosis, the treatment -
Proscia Inc., a data provider of solutions for digital pathology, has today announced the completion of its $ 1M seed round of financing. Proscia Pathology Cloud Platform which is already helping hundreds of pathologists and researchers will use the proceeds to accelerate growth and to pursue the vision of the company to unlock ideas and accelerate the discovery toward understanding and treating cancer.
The financing was led by Emerald Development Managers, with the participation of Robin Hood Ventures, Venture Capital and TCP A-Level Capital. "Our team is very impressed with the Proscia team, their vision and ability to execute," said Neil Cohen development managers Emerald, "They have a compelling pipeline of pathology solutions which will undoubtedly improve the diagnosis and cancer treatment. "
The Baltimore company was founded in 2014 by technicians from Johns Hopkins University and other academic institutions. The Proscia software, which includes machine learning, computer vision and cloud computing, recognizes the histological patterns in whole slide images and quantifies tissue manner not possible with the naked eye and microscope. "Quantitative techniques allow digital images to increase the field of pathology in new ways," said Dr. Liron Pantanowitz, director of IT Pathology at the University of Pittsburgh Medical Center, "In the end, with these capabilities, digital pathology will allow more accurate diagnoses. "UPMC and Proscia expect soon announce a partnership co-development to bring new quantitative tools state-of-the-art in digital pathology.
"Precision Medicine in the fight against cancer saves lives and long-term health care costs," said David West, Jr., President and CEO of Proscia " as digital imaging did for radiology, our software will usher in a new era of computer assisted pathology accelerate the fight against deadly diseases. We are pleased and grateful for the support of our investors to help us achieve our vision. "
The financing was led by Emerald Development Managers, with the participation of Robin Hood Ventures, Venture Capital and TCP A-Level Capital. "Our team is very impressed with the Proscia team, their vision and ability to execute," said Neil Cohen development managers Emerald, "They have a compelling pipeline of pathology solutions which will undoubtedly improve the diagnosis and cancer treatment. "
The Baltimore company was founded in 2014 by technicians from Johns Hopkins University and other academic institutions. The Proscia software, which includes machine learning, computer vision and cloud computing, recognizes the histological patterns in whole slide images and quantifies tissue manner not possible with the naked eye and microscope. "Quantitative techniques allow digital images to increase the field of pathology in new ways," said Dr. Liron Pantanowitz, director of IT Pathology at the University of Pittsburgh Medical Center, "In the end, with these capabilities, digital pathology will allow more accurate diagnoses. "UPMC and Proscia expect soon announce a partnership co-development to bring new quantitative tools state-of-the-art in digital pathology.
"Precision Medicine in the fight against cancer saves lives and long-term health care costs," said David West, Jr., President and CEO of Proscia " as digital imaging did for radiology, our software will usher in a new era of computer assisted pathology accelerate the fight against deadly diseases. We are pleased and grateful for the support of our investors to help us achieve our vision. "
EmoticonEmoticon